文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

重症监护室患者晚期血管升压药使用:一项回顾性队列研究

Late Vasopressor Administration in Patients in the ICU: A Retrospective Cohort Study.
PubMed 文献 · Chest · 2020-04-09
一句话结论在ICU住院≥4天的退伍军人中,5.5%出现晚期血管升压药使用,与仅早期使用相比,晚期使用与出院后1年死亡率升高相关(aHR 1.26)。

这项回顾性队列研究纳入2014至2017年退伍军人事务部ICU住院≥4天的62,206例次住院,将血管升压药使用时机分为早期(仅初始3天内)、晚期(第4天或以后且第3天未用)和持续(初始2天内至至少第4天)。晚期血管升压药使用发生率为5.5%(3,429/62,206)。合并症更多(每增加1个van Walraven分值,aOR 1.02;95%CI 1.02-1.03)和入院时病情更重(每增加1个百分点死亡风险,aOR 1.01;95%CI 1.01-1.02)的患者更可能接受晚期血管升压药治疗。与仅早期使用相比,持续使用(aHR 1.48;95%CI 1.33-1.65)和晚期使用(aHR 1.26;95%CI 1.15-1.38)的患者出院后1年死亡率更高。

要点

  • 在ICU住院≥4天的退伍军人中,晚期血管升压药使用(第4天或以后且第3天未用)发生率为5.5%(3,429/62,206)。
  • 合并症更多(每增加1个van Walraven分值,aOR 1.02;95%CI 1.02-1.03)和入院病情更重(每增加1个百分点死亡风险,aOR 1.01;95%CI 1.01-1.02)与晚期血管升压药使用相关。
  • 近50%的患者在接受晚期血管升压药治疗的24小时内开始使用一种新抗生素。
  • 与仅早期使用血管升压药相比,持续使用(aHR 1.48;95%CI 1.33-1.65)和晚期使用(aHR 1.26;95%CI 1.15-1.38)的患者出院后1年死亡率更高。

适用人群与场景

  • 2014至2017年入住退伍军人事务部ICU且住院时间≥4天的退伍军人。

诊断标准与关键阈值

  • 血管升压药使用时机分类:早期为仅在初始3天内使用;晚期为第4天或以后使用且第3天未使用;持续为初始2天内使用并持续至至少第4天。

研究设计与关键结果

  • 回顾性队列研究,纳入62,206例次ICU住院≥4天的住院,晚期血管升压药使用发生率为5.5%(3,429/62,206)。
  • 合并症更多(每增加1个van Walraven分值,aOR 1.02;95%CI 1.02-1.03)和入院时病情更重(每增加1个百分点死亡风险,aOR 1.01;95%CI 1.01-1.02)与接受晚期血管升压药治疗相关。
  • 近50%的患者在接受晚期血管升压药治疗的24小时内开始使用一种新抗生素。
  • 与仅早期使用血管升压药相比,持续使用(aHR 1.48;95%CI 1.33-1.65)和晚期使用(aHR 1.26;95%CI 1.15-1.38)的患者出院后1年死亡率更高。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,研究如何优化晚期血管升压药治疗的实施可能改善长期死亡率。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Little is known about the prevalence, predictors, and outcomes of late vasopressor administration which evolves after admission to the ICU.

RESEARCH QUESTION: What is the epidemiology of late vasopressor administration in the ICU?

STUDY DESIGN AND METHODS: We retrospectively studied a cohort of veterans admitted to the Veterans Administration ICUs for ≥ 4 days from 2014 to 2017. The timing of vasopressor administration was categorized as early (only within the initial 3 days), late (on day 4 or later and none on day 3), and continuous (within the initial 2 days through at least day 4). Regressions were performed to identify patient factors associated with late vasopressor administration and the timing of vasopressor administration with posthospitalization discharge mortality.

RESULTS: Among the 62,206 hospitalizations with at least 4 ICU days, late vasopressor administration occurred in 5.5% (3,429 of 62,206). Patients with more comorbidities (adjusted OR [aOR], 1.02 per van Walraven point; 95% CI, 1.02-1.03) and worse severity of illness on admission (aOR, 1.01 per percentage point risk of death; 95% CI, 1.01-1.02) were more likely to receive late vasopressor therapy. Nearly 50% of patients started a new antibiotic within 24 h of receiving late vasopressor therapy. One-year mortality after survival to discharge was higher for patients with continuous (adjusted hazard ratio [aHR], 1.48; 95% CI, 1.33-1.65) and late vasopressor administration (aHR, 1.26; 95% CI, 1.15-1.38) compared with only early vasopressor administration.

INTERPRETATION: Late vasopressor administration was modestly associated with comorbidities and admission illness severity. One-year mortality was higher among those who received late vasopressor administration compared with only early vasopressor administration. Research to understand optimization of late vasopressor therapy administration may improve long-term mortality.

来源:Chest,查看原文。版权归原作者所有。

参考来源

  1. Viglianti EM, Bagshaw SM, Bellomo R, et al. Late Vasopressor Administration in Patients in the ICU: A Retrospective Cohort Study. Chest. 2020. PMID: 32278780. doi:10.1016/j.chest.2020.02.071

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。